BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

432 related articles for article (PubMed ID: 29305587)

  • 1. Consensus molecular subtypes of colorectal cancer are recapitulated in in vitro and in vivo models.
    Linnekamp JF; Hooff SRV; Prasetyanti PR; Kandimalla R; Buikhuisen JY; Fessler E; Ramesh P; Lee KAST; Bochove GGW; de Jong JH; Cameron K; Leersum RV; Rodermond HM; Franitza M; Nürnberg P; Mangiapane LR; Wang X; Clevers H; Vermeulen L; Stassi G; Medema JP
    Cell Death Differ; 2018 Mar; 25(3):616-633. PubMed ID: 29305587
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Colorectal Cancer Consensus Molecular Subtypes Translated to Preclinical Models Uncover Potentially Targetable Cancer Cell Dependencies.
    Sveen A; Bruun J; Eide PW; Eilertsen IA; Ramirez L; Murumägi A; Arjama M; Danielsen SA; Kryeziu K; Elez E; Tabernero J; Guinney J; Palmer HG; Nesbakken A; Kallioniemi O; Dienstmann R; Lothe RA
    Clin Cancer Res; 2018 Feb; 24(4):794-806. PubMed ID: 29242316
    [No Abstract]   [Full Text] [Related]  

  • 3. Consensus molecular subtype classification of colorectal adenomas.
    Komor MA; Bosch LJ; Bounova G; Bolijn AS; Delis-van Diemen PM; Rausch C; Hoogstrate Y; Stubbs AP; de Jong M; Jenster G; van Grieken NC; Carvalho B; Wessels LF; Jimenez CR; Fijneman RJ; Meijer GA;
    J Pathol; 2018 Nov; 246(3):266-276. PubMed ID: 29968252
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Characterization of patients with sporadic colorectal cancer following the new Consensus Molecular Subtypes (CMS)].
    Wielandt AM; Villarroel C; Hurtado C; Simian D; Zamorano D; Martínez M; Castro M; Vial MT; Kronberg U; López-Kostner F
    Rev Med Chil; 2017 Apr; 145(4):419-430. PubMed ID: 28748988
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Value of Consensus Molecular Subtypes in Colorectal Cancer: A Systematic Review and Meta-Analysis.
    Ten Hoorn S; de Back TR; Sommeijer DW; Vermeulen L
    J Natl Cancer Inst; 2022 Apr; 114(4):503-516. PubMed ID: 34077519
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Establishment and characterization of cell lines from chromosomal instable colorectal cancer.
    Maletzki C; Gock M; Randow M; Klar E; Huehns M; Prall F; Linnebacher M
    World J Gastroenterol; 2015 Jan; 21(1):164-76. PubMed ID: 25574089
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CMScaller: an R package for consensus molecular subtyping of colorectal cancer pre-clinical models.
    Eide PW; Bruun J; Lothe RA; Sveen A
    Sci Rep; 2017 Nov; 7(1):16618. PubMed ID: 29192179
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Evolving Role of Consensus Molecular Subtypes: a Step Beyond Inpatient Selection for Treatment of Colorectal Cancer.
    Ros J; Baraibar I; Martini G; Salvà F; Saoudi N; Cuadra-Urteaga JL; Dienstmann R; Tabernero J; Élez E
    Curr Treat Options Oncol; 2021 Nov; 22(12):113. PubMed ID: 34741675
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The correlation between immune subtypes and consensus molecular subtypes in colorectal cancer identifies novel tumour microenvironment profiles, with prognostic and therapeutic implications.
    Soldevilla B; Carretero-Puche C; Gomez-Lopez G; Al-Shahrour F; Riesco MC; Gil-Calderon B; Alvarez-Vallina L; Espinosa-Olarte P; Gomez-Esteves G; Rubio-Cuesta B; Sarmentero J; La Salvia A; Garcia-Carbonero R
    Eur J Cancer; 2019 Dec; 123():118-129. PubMed ID: 31678770
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular pathological classification of colorectal cancer.
    Müller MF; Ibrahim AE; Arends MJ
    Virchows Arch; 2016 Aug; 469(2):125-34. PubMed ID: 27325016
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phenotypic subtypes predict outcomes in colorectal cancer.
    Kasurinen J; Beilmann-Lehtonen I; Kaprio T; Hagström J; Haglund C; Böckelman C
    Acta Oncol; 2023 Mar; 62(3):245-252. PubMed ID: 36867078
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The consensus molecular subtypes of colorectal cancer.
    Guinney J; Dienstmann R; Wang X; de Reyniès A; Schlicker A; Soneson C; Marisa L; Roepman P; Nyamundanda G; Angelino P; Bot BM; Morris JS; Simon IM; Gerster S; Fessler E; De Sousa E Melo F; Missiaglia E; Ramay H; Barras D; Homicsko K; Maru D; Manyam GC; Broom B; Boige V; Perez-Villamil B; Laderas T; Salazar R; Gray JW; Hanahan D; Tabernero J; Bernards R; Friend SH; Laurent-Puig P; Medema JP; Sadanandam A; Wessels L; Delorenzi M; Kopetz S; Vermeulen L; Tejpar S
    Nat Med; 2015 Nov; 21(11):1350-6. PubMed ID: 26457759
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bioactive Peptides Sensitize Cells to Anticancer Effects of Oxaliplatin in Human Colorectal Cancer Xenografts in Nude Mice.
    Li X; Xia L; Ouyang X; Suyila Q; Su L; Su X
    Protein Pept Lett; 2019; 26(7):512-522. PubMed ID: 30950338
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chrysophanol exhibits inhibitory activities against colorectal cancer by targeting decorin.
    Deng M; Xue Y; Xu L; Wang Q; Wei J; Ke X; Wang J; Chen X
    Cell Biochem Funct; 2020 Jan; 38(1):47-57. PubMed ID: 31710116
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Classification of patients with metastatic colorectal cancer into consensus molecular subtypes into real-world: A pilot study.
    González-Montero J; Burotto M; Valenzuela G; Mateluna D; Buen-Abad F; Toro J; Barajas O; Marcelain K
    World J Clin Oncol; 2023 Oct; 14(10):409-419. PubMed ID: 37970108
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of Consensus Molecular Subtypes and Molecular Markers With Clinical Outcomes in Patients With Metastatic Colorectal Cancer: Biomarker Analyses From LUME-Colon 1.
    Lenz HJ; Argiles G; Yoshino T; Tejpar S; Ciardiello F; Braunger J; Salnikov AV; Gabrielyan O; Schmid R; Höfler J; Kitzing T; Van Cutsem E
    Clin Colorectal Cancer; 2021 Mar; 20(1):84-95.e8. PubMed ID: 33041226
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Colorectal Cancer Cell Line Proteomes Are Representative of Primary Tumors and Predict Drug Sensitivity.
    Wang J; Mouradov D; Wang X; Jorissen RN; Chambers MC; Zimmerman LJ; Vasaikar S; Love CG; Li S; Lowes K; Leuchowius KJ; Jousset H; Weinstock J; Yau C; Mariadason J; Shi Z; Ban Y; Chen X; Coffey RJC; Slebos RJC; Burgess AW; Liebler DC; Zhang B; Sieber OM
    Gastroenterology; 2017 Oct; 153(4):1082-1095. PubMed ID: 28625833
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Clinically Applicable Gene-Expression Classifier Reveals Intrinsic and Extrinsic Contributions to Consensus Molecular Subtypes in Primary and Metastatic Colon Cancer.
    Piskol R; Huw L; Sergin I; Kljin C; Modrusan Z; Kim D; Kljavin N; Tam R; Patel R; Burton J; Penuel E; Qu X; Koeppen H; Sumiyoshi T; de Sauvage F; Lackner MR; de Sousa E Melo F; Kabbarah O
    Clin Cancer Res; 2019 Jul; 25(14):4431-4442. PubMed ID: 31004000
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological Inhibition of TFF3 Enhances Sensitivity of CMS4 Colorectal Carcinoma to 5-Fluorouracil through Inhibition of p44/42 MAPK.
    Chen RM; Chiou YS; Chong QY; Poh HM; Tan TZ; Zhang MY; Ma L; Zhu T; Pandey V; Basappa ; Kumar AP; Lobie PE
    Int J Mol Sci; 2019 Dec; 20(24):. PubMed ID: 31835445
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Host-microbiota interactions contributing to the heterogeneous tumor microenvironment in colorectal cancer.
    Li X; Wu D; Li Q; Gu J; Gao W; Zhu X; Yin W; Zhu R; Zhu L; Jiao N
    Physiol Genomics; 2024 Feb; 56(2):221-234. PubMed ID: 38073489
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.